Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-26 @ 11:11 AM
Ignite Modification Date:
2025-12-26 @ 11:11 AM
NCT ID:
NCT01604928
Brief Summary:
The study is intended to test efficacy, safety and tolerability of two doses of YM178 against placebo and tolterodine to treat patients with symptoms of over active bladder.
Detailed Description:
This is a multinational, multicenter, double-blind, double-dummy,
randomized, parallel group, placebo and active controlled phase II proof-of concept study. Patients are enrolled into a single-blind, 2-week placebo run in
period after which they are randomized to 4 weeks of double-blind
treatment with YM178 (low dose and high dose), placebo or tolterodine. Subsequently patients will be followed for an additional 2 weeks
with single-blind placebo treatment. There are 6 visits in total: visit 1 at
enrolment, visit 2 (baseline) after the 2-week placebo run-in, visits 3, 4 and 5
after 1, 2 and 4 weeks of double-blind treatment respectively, and visit 6
after a 2-week follow-up.
Study:
NCT01604928
Study Brief:
Protocol Section:
NCT01604928